Using bispecific antibodies in forced degradation studies to analyze the structure–function relationships of symmetrically and asymmetrically modified antibodies

References

• Ecker DM, Jones SD, Levine HL. The therapeutic monoclonal antibody market. mAbs. 2015;7(1):9–14. doi:10.4161/19420862.2015.989042.
   PubMed Web of Science ®Google Scholar
• Beck A, Wagner-Rousset E, Ayoub D, Van Dorsselaer A, Sanglier-Cianferani S. Characterization of therapeutic antibodies and related products. Anal Chem. 2013;85(2):715–36. doi:10.1021/ac3032355.
   PubMed Web of Science ®Google Scholar
• Buss NA, Henderson SJ, McFarlane M, Shenton JM, de Haan L. Monoclonal antibody therapeutics: history and future. Curr Opin Pharmacol. 2012;12(5):615–22. doi:10.1016/j.coph.2012.08.001.
   PubMed Web of Science ®Google Scholar
• Beck A, Sanglier-Cianferani S, Van Dorsselaer A. Biosimilar, biobetter, and next generation antibody characterization by mass spectrometry. Anal Chem. 2012;84(11):4637–46. doi:10.1021/ac3002885.
   PubMed Web of Science ®Google Scholar
• Thompson NJ, Rosati S, Heck AJ. Performing native mass spectrometry analysis on therapeutic antibodies. Methods. 2014;65(1):11–17. doi:10.1016/j.ymeth.2013.05.003.
   PubMed Web of Science ®Google Scholar
• Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000;6(4):443–46. doi:10.1038/74704.
   PubMed Web of Science ®Google Scholar
• Raju TS. Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr Opin Immunol. 2008;20(4):471–78. doi:10.1016/j.coi.2008.06.007.
   PubMed Web of Science ®Google Scholar
• Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol. 2006;6(5):343–57. doi:10.1038/nri1837.
   PubMed Web of Science ®Google Scholar
• Yang Y, Wang G, Song T, Lebrilla CB, Heck AJR. Resolving the micro-heterogeneity and structural integrity of monoclonal antibodies by hybrid mass spectrometric approaches. mAbs. 2017;9(4):638–645. doi:10.1080/19420862.2017.1290033.
   Web of Science ®Google Scholar
• Qi P, Volkin DB, Zhao H, Nedved ML, Hughes R, Bass R, Yi SC, Panek ME, Wang D, Dalmonte P, et al. Characterization of the photodegradation of a human IgG1 monoclonal antibody formulated as a high-concentration liquid dosage form. J Pharm Sci. 2009;98(9):3117–30. doi:10.1002/jps.21617.
   PubMed Web of Science ®Google Scholar
• Hmiel LK, Brorson KA, Boyne MT. 2nd, Post-translational structural modifications of immunoglobulin G and their effect on biological activity. Anal Bioanal Chem. 2015;407(1):79–94. doi:10.1007/s00216-014-8108-x.
   PubMed Web of Science ®Google Scholar
• Liu H, Gaza-Bulseco G, Faldu D, Chumsae C, Sun J. Heterogeneity of monoclonal antibodies. J Pharm Sci. 2008;97(7):2426–47. doi:10.1002/jps.21180.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Pan H, Chen X. Mass spectrometry for structural characterization of therapeutic antibodies. Mass Spectrom Rev. 2009;28(1):147–76. doi:10.1002/mas.20190.
   PubMed Web of Science ®Google Scholar
• Pace AL, Wong RL, Zhang YT, Kao YH, Wang YJ. Asparagine deamidation dependence on buffer type, pH, and temperature. J Pharm Sci. 2013;102(6):1712–23. doi:10.1002/jps.23529.
   PubMed Web of Science ®Google Scholar
• Zhang YT, Hu J, Pace AL, Wong R, Wang YJ, Kao YH. Characterization of asparagine 330 deamidation in an Fc-fragment of IgG1 using cation exchange chromatography and peptide mapping. J Chromatogr B Analyt Technol Biomed Life Sci. 2014;965:65–71. doi:10.1016/j.jchromb.2014.06.018.
   PubMed Web of Science ®Google Scholar
• Bertolotti-Ciarlet A, Wang W, Lownes R, Pristatsky P, Fang Y, McKelvey T, Li Y, Li Y, Drummond J, Prueksaritanont T, et al. Impact of methionine oxidation on the binding of human IgG1 to Fc Rn and Fc gamma receptors. Mol Immunol. 2009;46(8–9):1878–82. doi:10.1016/j.molimm.2009.02.002.
   PubMed Web of Science ®Google Scholar
• Viski K, Gengeliczki Z, Lenkey K, Baranyane Ganzler K. Parallel development of chromatographic and mass-spectrometric methods for quantitative analysis of glycation on an IgG1 monoclonal antibody. J Chromatogr B Analyt Technol Biomed Life Sci. 2016;1032:198–204. doi:10.1016/j.jchromb.2016.04.043.
   PubMed Web of Science ®Google Scholar
• Hawe A, Wiggenhorn M, van de Weert M, Garbe JH, Mahler HC, Jiskoot W. Forced degradation of therapeutic proteins. J Pharm Sci. 2012;101(3):895–913. doi:10.1002/jps.22812.
   PubMed Web of Science ®Google Scholar
• Abdiche YN, Yeung YA, Chaparro-Riggers J, Barman I, Strop P, Chin SM, Pham A, Bolton G, McDonough D, Lindquist K, et al. The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity. mAbs. 2015;7(2):331–43. doi:10.1080/19420862.2015.1008353.
   PubMed Web of Science ®Google Scholar
• Okazaki A, Shoji-Hosaka E, Nakamura K, Wakitani M, Uchida K, Kakita S, Tsumoto K, Kumagai I, Shitara K. Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa. J Mol Biol. 2004;336(5):1239–49. doi:10.1016/j.jmb.2004.01.007.
   PubMed Web of Science ®Google Scholar
• Shields RL, Lai J, Keck R, O’Connell LY, Hong K, Meng YG, Weikert SH, Presta LG. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem. 2002;277(30):26733–40. doi:10.1074/jbc.M202069200.
   PubMed Web of Science ®Google Scholar
• Shatz W, Chung S, Li B, Marshall B, Tejada M, Phung W, Sandoval W, Kelley RF, Scheer JM. Knobs-into-holes antibody production in mammalian cell lines reveals that asymmetric afucosylation is sufficient for full antibody-dependent cellular cytotoxicity. mAbs. 2013;5(6):872–81. doi:10.4161/mabs.26307.
   PubMed Web of Science ®Google Scholar
• Ha S, Ou Y, Vlasak J, Li Y, Wang S, Vo K, Du Y, Mach A, Fang Y, Zhang N. Isolation and characterization of IgG1 with asymmetrical Fc glycosylation. Glycobiology. 2011;21(8):1087–96. doi:10.1093/glycob/cwr047.
   PubMed Web of Science ®Google Scholar
• Kontermann RE, Brinkmann U. Bispecific antibodies. Drug Discov Today. 2015;20(7):838–47. doi:10.1016/j.drudis.2015.02.008.
   PubMed Web of Science ®Google Scholar
• Sedykh SE, Prinz VV, Buneva VN, Nevinsky GA. Bispecific antibodies: design, therapy, perspectives. Drug Des Devel Ther. 2018;12:195–208. doi:10.2147/DDDT.S151282.
   PubMed Web of Science ®Google Scholar
• Liu Z, Gunasekaran K, Wang W, Razinkov V, Sekirov L, Leng E, Sweet H, Foltz I, Howard M, Rousseau AM, et al. Asymmetrical Fc engineering greatly enhances antibody-dependent cellular cytotoxicity (ADCC) effector function and stability of the modified antibodies. J Biol Chem. 2014;289(6):3571–90. doi:10.1074/jbc.M113.513366.
   PubMed Web of Science ®Google Scholar
• Goulet DR, Orcutt SJ, Zwolak A, Rispens T, Labrijn AF, de Jong RN, Atkins WM, Chiu ML. Kinetic mechanism of controlled Fab-arm exchange for the formation of bispecific immunoglobulin G1 antibodies. J Biol Chem. 2018;293(2):651–61. doi:10.1074/jbc.RA117.000303.
   PubMed Web of Science ®Google Scholar
• Gramer MJ, van Den Bremer ET, van Kampen MD, Kundu A, Kopfmann P, Etter E, Stinehelfer D, Long J, Lannom T, Noordergraaf EH, et al. Production of stable bispecific IgG1 by controlled Fab-arm exchange: scalability from bench to large-scale manufacturing by application of standard approaches. mAbs. 2013;5(6):962–73. doi:10.4161/mabs.26233.
   PubMed Web of Science ®Google Scholar
• Labrijn AF, Meesters JI, Priem P, de Jong RN, van Den Bremer ET, van Kampen MD, Gerritsen AF, Schuurman J, Parren PW. Controlled Fab-arm exchange for the generation of stable bispecific IgG1. Nat Protoc. 2014;9(10):2450–63. doi:10.1038/nprot.2014.169.
   PubMed Web of Science ®Google Scholar
• Labrijn AF, Meesters JI, de Goeij BE, van Den Bremer ET, Neijssen J, van Kampen MD, Strumane K, Verploegen S, Kundu A, Gramer MJ, et al. Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Proc Natl Acad Sci U S A. 2013;110(13):5145–50. doi:10.1073/pnas.1220145110.
   PubMed Web of Science ®Google Scholar
• Protection, M. D. o. E. Hydrogen peroxide, peracetic acid, and sodium percarbonate. Boston (MA): Massachusetts Department of Agricultural Resources; 2010, 1–15.
   Google Scholar
• Liu D, Ren D, Huang H, Dankberg J, Rosenfeld R, Cocco MJ, Li L, Brems DN, Remmele RL Jr. Structure and stability changes of human IgG1 Fc as a consequence of methionine oxidation. Biochemistry. 2008;47(18):5088–100. doi:10.1021/bi702238b.
   PubMed Web of Science ®Google Scholar
• An Y, Zhang Y, Mueller HM, Shameem M, Chen X. A new tool for monoclonal antibody analysis: application of IdeS proteolysis in IgG domain-specific characterization. mAbs. 2014;6(4):879–93. doi:10.4161/mabs.28762.
   PubMed Web of Science ®Google Scholar
• Sokolowska I, Mo J, Dong J, Lewis MJ, Hu P. Subunit mass analysis for monitoring antibody oxidation. mAbs. 2017;9(3):498–505. doi:10.1080/19420862.2017.1279773.
   PubMed Web of Science ®Google Scholar
• Mo J, Yan Q, So CK, Soden T, Lewis MJ, Hu P. Understanding the impact of methionine oxidation on the biological functions of IgG1 antibodies using hydrogen/deuterium exchange mass spectrometry. Anal Chem. 2016;88(19):9495–502. doi:10.1021/acs.analchem.6b01958.
   PubMed Web of Science ®Google Scholar
• Gao X, Ji JA, Veeravalli K, Wang YJ, Zhang T, McGreevy W, Zheng K, Kelley RF, Laird MW, Liu J, et al. Effect of individual Fc methionine oxidation on FcRn binding: met252 oxidation impairs FcRn binding more profoundly than Met428 oxidation. J Pharm Sci. 2015;104(2):368–77. doi:10.1002/jps.24136.
   PubMed Web of Science ®Google Scholar
• Haberger M, Bomans K, Diepold K, Hook M, Gassner J, Schlothauer T, Zwick A, Spick C, Kepert JF, Hienz B, et al. Assessment of chemical modifications of sites in the CDRs of recombinant antibodies: susceptibility vs. functionality of critical quality attributes. mAbs. 2014;6(2):327–39. doi:10.4161/mabs.27876.
   PubMed Web of Science ®Google Scholar
• Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 2014;5:520. doi:10.3389/fimmu.2014.00520.
   PubMed Web of Science ®Google Scholar
• Wang W, Vlasak J, Li Y, Pristatsky P, Fang Y, Pittman T, Roman J, Wang Y, Prueksaritanont T, Ionescu R. Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies. Mol Immunol. 2011;48(6–7):860–66. doi:10.1016/j.molimm.2010.12.009.
   PubMed Web of Science ®Google Scholar
• Putnam WS, Prabhu S, Zheng Y, Subramanyam M, Wang YM. Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies for monoclonal antibodies. Trends Biotechnol. 2010;28(10):509–16. doi:10.1016/j.tibtech.2010.07.001.
   PubMed Web of Science ®Google Scholar
• Goetze AM, Schenauer MR, Flynn GC. Assessing monoclonal antibody product quality attribute criticality through clinical studies. mAbs. 2010;2(5):500–07. doi:10.4161/mabs.2.5.12897.
   PubMed Web of Science ®Google Scholar
• van Beers MM, Bardor M. Minimizing immunogenicity of biopharmaceuticals by controlling critical quality attributes of proteins. Biotechnol J. 2012;7(12):1473–84. doi:10.1002/biot.201200065.
   PubMed Web of Science ®Google Scholar
• Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–75. doi:10.1007/s11095-009-0045-6.
   PubMed Web of Science ®Google Scholar
• Alt N, Zhang TY, Motchnik P, Taticek R, Quarmby V, Schlothauer T, Beck H, Emrich T, Harris RJ. Determination of critical quality attributes for monoclonal antibodies using quality by design principles. Biol J Int Assoc Biol Standardization. 2016;44(5):291–305. doi:10.1016/j.biologicals.2016.06.005.
   Google Scholar
• Wang W, Singh S, Zeng DL, King K, Nema S. Antibody structure, instability, and formulation. J Pharm Sci. 2007;96(1):1–26. doi:10.1002/jps.20727.
   PubMed Web of Science ®Google Scholar
• Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov. 2009;8(3):226–34. doi:10.1038/nrd2804.
   PubMed Web of Science ®Google Scholar
• Krah S, Sellmann C, Rhiel L, Schroter C, Dickgiesser S, Beck J, Zielonka S, Toleikis L, Hock B, Kolmar H, et al. Engineering bispecific antibodies with defined chain pairing. N Biotechnol. 2017;39(Pt B):167–73. doi:10.1016/j.nbt.2016.12.010.
   PubMed Web of Science ®Google Scholar
• Brinkmann U, Kontermann RE. The making of bispecific antibodies. mAbs. 2017;9(2):182–212. doi:10.1080/19420862.2016.1268307.
   PubMed Web of Science ®Google Scholar
• Zhang A, Hu P, MacGregor P, Xue Y, Fan H, Suchecki P, Olszewski L, Liu A. Understanding the conformational impact of chemical modifications on monoclonal antibodies with diverse sequence variation using hydrogen/deuterium exchange mass spectrometry and structural modeling. Anal Chem. 2014;86(7):3468–75. doi:10.1021/ac404130a.
   PubMed Web of Science ®Google Scholar
• Popov S, Hubbard JG, Kim J, Ober B, Ghetie V, Ward ES. The stoichiometry and affinity of the interaction of murine Fc fragments with the MHC class I-related receptor, FcRn. Mol Immunol. 1996;33:521–30.
   PubMed Web of Science ®Google Scholar
• West AP Jr., Bjorkman PJ. Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor(,). Biochemistry. 2000;39:9698–708.
   PubMed Web of Science ®Google Scholar
• Raghavan M, Wang Y, Bjorkman PJ. Effects of receptor dimerization on the interaction between the class I major histocompatibility complex-related Fc receptor and IgG. Proc Natl Acad Sci U S A. 1995;92(24):11200–04. doi:10.1073/pnas.92.24.11200.
   PubMed Web of Science ®Google Scholar
• Sjodahl J. Structural studies on the four repetitive Fc-binding regions in protein A from Staphylococcus aureus. Eur J Biochem. 1977;78:471–90.
   PubMedGoogle Scholar
• Gaza-Bulseco G, Faldu S, Hurkmans K, Chumsae C, Liu H. Effect of methionine oxidation of a recombinant monoclonal antibody on the binding affinity to protein A and protein G. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;870(1):55–62. doi:10.1016/j.jchromb.2008.05.045.
   PubMed Web of Science ®Google Scholar
• Phillips JJ, Buchanan A, Andrews J, Chodorge M, Sridharan S, Mitchell L, Burmeister N, Kippen AD, Vaughan TJ, Higazi DR, et al. Rate of asparagine deamidation in a monoclonal antibody correlating with hydrogen exchange rate at adjacent downstream residues. Anal Chem. 2017;89(4):2361–68. doi:10.1021/acs.analchem.6b04158.
   PubMed Web of Science ®Google Scholar
• Sondermann P, Huber R, Oosthuizen V, Jacob U. The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex. Nature. 2000;406(6793):267–73. doi:10.1038/35018508.
   PubMed Web of Science ®Google Scholar
• Klein C, Sustmann C, Thomas M, Stubenrauch K, Croasdale R, Schanzer J, Brinkmann U, Kettenberger H, Regula JT, Schaefer W. Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies. mAbs. 2012;4(6):653–63. doi:10.4161/mabs.21379.
   PubMed Web of Science ®Google Scholar
• Labrijn AF, Rispens T, Meesters J, Rose RJ, Den Bleker TH, Loverix S, van Den Bremer ET, Neijssen J, Vink T, Lasters I, et al. Species-specific determinants in the IgG CH3 domain enable Fab-arm exchange by affecting the noncovalent CH3-CH3 interaction strength. J Immunol. 2011;187(6):3238–46. doi:10.4049/jimmunol.1003336.
   PubMed Web of Science ®Google Scholar
• Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, Chan C, Chung HS, Eivazi A, Yoder SC, et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A. 2006;103(11):4005–10. doi:10.1073/pnas.0508123103.
   PubMed Web of Science ®Google Scholar
• Li T, DiLillo DJ, Bournazos S, Giddens JP, Ravetch JV, Wang LX. Modulating IgG effector function by Fc glycan engineering. Proc Natl Acad Sci U S A. 2017;114(13):3485–90. doi:10.1073/pnas.1702173114.
   PubMed Web of Science ®Google Scholar
• Pace D, Lewis N, Wu T, Gillespie R, Leiske D, Velayudhan J, Rohrbach A, Connell-Crowley L. Characterizing the effect of multiple Fc glycan attributes on the effector functions and FcgammaRIIIa receptor binding activity of an IgG1 antibody. Biotechnol Prog. 2016;32(5):1181–92. doi:10.1002/btpr.2300.
   PubMed Web of Science ®Google Scholar
• Lanier LL, Kipps TJ, Phillips JH. Functional properties of a unique subset of cytotoxic CD3+ T lymphocytes that express Fc receptors for IgG (CD16/Leu-11 antigen). J Exp Med. 1985;162(6):2089–106. doi:10.1084/jem.162.6.2089.
   PubMed Web of Science ®Google Scholar
• Kellner C, Derer S, Valerius T, Peipp M. Boosting ADCC and CDC activity by Fc engineering and evaluation of antibody effector functions. Methods. 2014;65(1):105–13. doi:10.1016/j.ymeth.2013.06.036.
   PubMed Web of Science ®Google Scholar
• Manzke O, Tesch H, Diehl V, Bohlen H. Single-step purification of bispecific monoclonal antibodies for immunotherapeutic use by hydrophobic interaction chromatography. J Immunol Methods. 1997;208:65–73.
   PubMed Web of Science ®Google Scholar